<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Naturae</journal-id><journal-id journal-id-type="iso-abbrev">Acta Naturae</journal-id><journal-id journal-id-type="publisher-id">ActaNaturae</journal-id><journal-title-group><journal-title>Acta Naturae</journal-title></journal-title-group><issn pub-type="ppub">2075-8251</issn><publisher><publisher-name>A.I. Gordeyev</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6977952</article-id><article-id pub-id-type="doi">10.32607/20758251-2019-11-4-22-32</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject><subj-group><subject>Molecular Biology</subject></subj-group></subj-group></article-categories><title-group><article-title>Non-neutralizing Antibodies Directed at Conservative Influenza Antigens</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sedova</surname><given-names>E. S.</given-names></name><xref ref-type="aff" rid="AF1"/><email>sedova-es@yandex.ru</email></contrib><contrib contrib-type="author"><name><surname>Scherbinin</surname><given-names>D. N.</given-names></name><xref ref-type="aff" rid="AF1"/></contrib><contrib contrib-type="author"><name><surname>Lysenko</surname><given-names>A. A.</given-names></name><xref ref-type="aff" rid="AF1"/></contrib><contrib contrib-type="author"><name><surname>Alekseeva</surname><given-names>S. V.</given-names></name><xref ref-type="aff" rid="AF1"/></contrib><contrib contrib-type="author"><name><surname>Artemova</surname><given-names>E. A.</given-names></name><xref ref-type="aff" rid="AF1"/></contrib><contrib contrib-type="author"><name><surname>Shmarov</surname><given-names>M. M.</given-names></name><xref ref-type="aff" rid="AF1"/></contrib></contrib-group><aff id="AF1">Federal Research Centre for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya of the Ministry of Health of the Russian Federation, Moscow, 123098 Russia</aff><pub-date pub-type="ppub"><season>Oct-Dec</season><year>2019</year></pub-date><volume>11</volume><issue>4</issue><fpage>22</fpage><lpage>32</lpage><history><date date-type="received"><day>16</day><month>6</month><year>2019</year></date><date date-type="accepted"><day>21</day><month>9</month><year>2019</year></date></history><permissions><copyright-statement>Copyright &#x000ae; 2019 National Research University Higher School of Economics.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>
This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.
</license-p></license></permissions><abstract><p>
At the moment, developing new broad-spectrum influenza vaccines which would
help avoid annual changes in a vaccine&#x02019;s strain set is urgency. In
addition, developing new vaccines based on highly conserved influenza virus
proteins could allow us to better prepare for potential pandemics and
significantly reduce the damage they cause. Evaluation of the humoral response
to vaccine administration is a key aspect of the characterization of the
effectiveness of influenza vaccines. In the development of new broad-spectrum
influenza vaccines, it is important to study the mechanisms of action of
various antibodies, including non-neutralizing ones, as well as to be in the
possession of methods for quantifying these antibodies after immunization with
new vaccines against influenza. In this review, we focused on the mechanisms of
anti-influenza action of non-neutralizing antibodies, such as
antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular
phagocytosis (ADCP), and antibody-mediated complement-dependent cytotoxicity
(CDC). The influenza virus antigens that trigger these reactions are
hemagglutinin (HA) and neuraminidase (NA), as well as highly conserved
antigens, such as M2 (ion channel), M1 (matrix protein), and NP
(nucleoprotein). In addition, the mechanisms of action and methods for
detecting antibodies to neuraminidase (NA) and to the stem domain of
hemagglutinin (HA) of the influenza virus are considered.
</p></abstract><kwd-group kwd-group-type="author"><kwd>influenza virus</kwd><kwd>broad-spectrum influenza vaccine</kwd><kwd>antibody-dependent cellular cytotoxicity</kwd><kwd>antibody-dependent cellular phagocytosis</kwd><kwd>antibody-mediated complement-dependent cytotoxicity</kwd></kwd-group></article-meta></front><body><sec><title>INTRODUCTION</title><p>
Influenza is a highly contagious infection; it is responsible for annual
epidemics and periodical pandemics that appear at varied intervals. According
to the WHO, 20&#x02013;30% of children and 5 to 10% of adults are infected with
influenza annually in the world and 250 to 500 thousand people die from severe
complications of the influenza infection. In pandemics, the extent of
complications and mortality increase significantly. For instance, according to
various sources, around 50 to 100 million people died from influenza during the
1918&#x02013;1919 flu pandemic [<xref rid="R1" ref-type="bibr">1</xref>].
</p><p>
The most potent protective measure against the influenza infection and its
spread is vaccination. Modern influenza vaccines, as a rule, induce the
formation of antibodies to the influenza HA and NA surface antigens. The
surface proteins of the influenza virus undergo constant antigenic drift.
Therefore, annual renewal of the strain composition of the vaccine is required
[<xref rid="R2" ref-type="bibr">2</xref>].
</p><p>
To date, the development of new broad-spectrum influenza vaccines which would
help avoid the necessity of annual changes in the strain composition of the
vaccine remains urgency. In addition, the creation of new vaccines based on
highly conserved influenza virus proteins would allow us to better prepare for
potential pandemics and significantly reduce the damage they cause.
</p><p>
The key to evaluating the effectiveness of influenza vaccines is to determine
the level of humoral response after vaccination. Neutralizing antibodies to the
globular head domain of hemagglutinin are produced during viral infection and
undergird the protective mechanisms of all the influenza vaccines available to
date [<xref rid="R3" ref-type="bibr">3</xref>]. Most virus-neutralizing
antibodies bind to the head domain of HA, inhibit the binding of HA to the
sialic acid residue and prevent the virus from entering the
cells <italic>(<xref ref-type="fig" rid="F1">Fig. 1, b</xref>)</italic>.
These antibodies are determined by conventional
hemagglutination inhibition and neutralization reactions
[<xref rid="R4" ref-type="bibr">4</xref>-<xref rid="R6" ref-type="bibr">6</xref>]. Moreover,
many HA head-specific antibodies are also able to inhibit the release of the virus from
the cell <italic>(<xref ref-type="fig" rid="F1">Fig. 1, d</xref>)</italic>.
This defense mechanism cannot be
evaluated by conventional hemagglutination inhibition and neutralization
inhibition assays; it is detected by adding antibodies to cells that have been
previously infected with the influenza virus [<xref rid="R7" ref-type="bibr">7</xref>].
</p><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>
Mechanisms of action of anti-influenza antibodies. The influenza virus enters
the body through respiratory tract mucosa, where viral hemagglutinin (HA) binds
to the terminal sialic acids of mucin. Neuraminidase (NA) releases the virus by
cleaving the terminal sialic acid residues. Antibodies to neuraminidase can
inhibit the reaction, and the virus would not be able to penetrate the mucous
layer <bold>(a)</bold>. After penetrating the mucous layer, the influenza virus
binds to the sialic acids on the surface of the target cells and enters the
cell by endocytosis. Neutralizing antibodies bind to influenza HA and block
this process <bold>(b).</bold>The endosomes of the target cells become
acidified, thus triggering the fusion of the endosomal and viral membranes via
HA, which results in the release of the viral genome into the cell cytoplasm.
Antibodies to the stem domain of HA can inhibit this process
<bold>(c).</bold>After the synthesis of viral proteins, the internal proteins
are packed into viral particles containing HA, NA, and the M2 ion channel
molecules on the virion surface. On the cell surface, the HA, NA, and M2
proteins can be bound by antibodies that block the budding of viral particles.
Maturing viral particles are covered by the host cell membrane as a result of
the interaction between HA and sialic acids. Meanwhile, NA cleaves terminal
sialic acids from the virus, while antibodies to NA can inhibit this process
<bold>(d)</bold>. Finally, in the matured viral particles, HA0 is cleaved into
the HA1 and HA2 subunits by the host proteases that are present in the
respiratory tract. Antibodies directed to the HA stem domain can block this
process <bold>(e).</bold>In addition, viral antigens exposed to the surface of
an infected cell (including the internal protein NP, which is detected on the
surface of the infected cell) are targets for antibodies that activate effector
cells via the Fc-FcR interaction <bold>(f).</bold>Antibodies directed to the
viral antigens exposed on the cell surface can also activate the complement
system <bold>(g) </bold>
</p></caption><graphic xlink:href="AN20758251-11-04-022-g001"/></fig><p>
Antibodies against various conserved antigens of the influenza virus (such as
NP, M1, M2) are generally non-neutralizing in nature and cannot prevent the
development of the viral infection. However, they are able to exert a
protective function through various immune mechanisms. Thus, the study of the
mechanisms of action of various antibodies, including non-neutralizing ones, as
well as the development of methods for evaluating the level of such antibodies
after immunization with new influenza vaccines, is relevant for the development
of novel broad-spectrum influenza vaccines.
</p></sec><sec><title>ANTIBODIES TO CONSERVED ANTIGENS OF THE INFLUENZA VIRUS PARTICIPATING IN THE REACTIONS OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY, ANTIBODY-DEPENDENT PHAGOCYTOSIS, AND ANTIBODY-MEDIATED COMPLEMENT-DEPENDENT CYTOTOXICITY</title><p>
The ability of antibodies to neutralize the influenza virus has traditionally
been considered the most important mechanism of protection against influenza.
However, recent studies have shown the importance of other antibody-mediated
effects, which also contribute to antiviral protection [<xref rid="R3" ref-type="bibr">3</xref>]. The following mechanisms of anti-influenza action are
realized by non-neutralizing antibodies: antibody-dependent cellular
cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and
antibody-mediated complement-dependent cytotoxicity (CDC) [<xref rid="R8" ref-type="bibr">8</xref>]. The influenza virus antigens that trigger
these reactions are HA, NA, and highly conserved antigens such as the M2 ion
channel, M1 matrix protein, and nucleoprotein (NP).
</p><p>
Unlike neutralizing antibodies, the functions of which are implemented by the
variable regions, the effect of non-neutralizing antibodies depends on the
conserved Fc region. The Fc region is able to interact with various components
of the immune system, while the variable part of the antibody binds to the
antigen. The most significant antibody isotypes for the implementation of the
effector functions of non-neutralizing antibodies are IgG and IgM, with IgG3
possessing the highest functional potential [<xref rid="R9" ref-type="bibr">9</xref>].
</p><p>
Neutralizing antibodies can bind with their Fc region to the specific Fc
receptors exposed on the surface of most immune cells, including NK cells,
macrophages, and
neutrophils <italic>(<xref ref-type="fig" rid="F1">Fig. 1, f</xref>)</italic>.
After binding to
antibodies, these immune cells are activated and become involved in the defense
response against a pathogen. A total of six different receptors involved in the
activation (Fc&#x003b3;RI, IIA, IIC, IIIA, and IIIB) or inhibition
(Fc&#x003b3;RIIB1/B2) of human immune cells have been described. Non-neutralizing
antibodies can also activate the complement
system <italic>(<xref ref-type="fig" rid="F1">Fig. 1, g</xref>)</italic>
[<xref rid="R9" ref-type="bibr">9</xref>].
</p><p>
<bold>Antibody-dependent cellular cytotoxicity (ADCC)</bold>
</p><p>
Influenza virus-infected cells carry viral proteins on their surface &#x02013;
mainly HA and NA &#x02013; since new virions are formed by budding from the cell
membrane. Anti-influenza IgG can bind viral proteins on the cell surface, thus
opsonizing the infected cells. The Fc gamma receptor IIIa (Fc&#x003b3;RIIIa)
exposed on the surface of many cells of the innate immune response, such as NK
cells, monocytes, and macrophages, binds to the Fc region of IgG. The
interaction between Fc&#x003b3;RIIIa and IgG bound to the infected cell leads to
phosphorylation of the tyrosine-based activation motif (ITAM) and activation of
the Ca<sup>2+</sup>-dependent signaling pathway. As a result, NK cells begin to
produce cytotoxic factors (perforins and granzymes), which lead to the death of
the infected cell, and antiviral cytokines (IFN&#x003b3;, TNF&#x003b1;) and
chemokines <italic>(<xref ref-type="fig" rid="F2">Fig. 2</xref>)</italic>
[<xref rid="R10" ref-type="bibr">10</xref>].
</p><fig id="F2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>
The mechanism of antibody-dependent cellular cytotoxicity (ADCC) in a cell
infected with an influenza virus. IgG binds to the viral antigens on the
surface of the infected cell. NK cells recognize the infected cells via Fc-FcR
interactions and then release cytotoxic granules and secrete antiviral
cytokines
</p></caption><graphic xlink:href="AN20758251-11-04-022-g002"/></fig><p>
One of the main targets for the antibodies involved in ADCC is the conserved
stem of HA, which is one of the most represented surface proteins of the
influenza virus. For instance, it has been shown that antibodies with a broad
spectrum of activity against the conserved HA stem protect mice from a lethal
influenza infection through a mechanism that involves an interaction with
Fc-Fc&#x003b3;R. On the contrary, the protective activity of antibodies in
relation to the variable head domain of HA has manifested itself both in the
presence and absence of an interaction with Fc&#x003b3;R [<xref rid="R11" ref-type="bibr">11</xref>].
</p><p>
Furthermore, re-infection of macaques with the influenza virus has led to a
rapid appearance of ADCC responses. Antibodies capable of inducing activation
of NK cells were found in the bronchoalveolar lavages of the macaques, which
correlated with a reduced virus shedding and decreased disease duration [<xref rid="R12" ref-type="bibr">12</xref>]. In humans, high titers of antibodies
capable of participating in ADCC were also shown to correlate with a decrease
in the incidence of an experimental infection [<xref rid="R13" ref-type="bibr">13</xref>]. Moreover, elderly people who had previously been infected
with viruses close to the strain that caused the 2009 swine influenza pandemic
and who retained a significant amount of titers of the antibodies participating
in ADCC but had no neutralizing antibodies were protected from the pandemic
influenza virus. Thus, non-neutralizing HA stem-specific antibodies capable of
inducing ADCC are directly related to the level of protection against an
influenza virus [<xref rid="R14" ref-type="bibr">14</xref>]. In addition,
according to published data, vaccines against seasonal influenza viruses weakly
induce the production of antibodies that can participate in ADCC, while the
presence of NK cell-activating antibodies with a broad spectrum of activity in
elderly people suggests that these antibodies accumulate over a lifetime as a
result of re-infection with various influenza virus strains [<xref rid="R15" ref-type="bibr">15</xref>].
</p><p>
Using a panel of 13 monoclonal antibodies to the influenza virus HA protein
(both neutralizing and non-neutralizing ones, both stem- and head-specific
ones), DiLillo et al. [<xref rid="R16" ref-type="bibr">16</xref>] showed that
Fc-Fc&#x003b3;R interactions are necessary for all broad-spectrum antibodies in
order to ensure <italic>in vivo </italic>protection. A similar result was
obtained by comparing two NA-specific antibodies, one of which had a broad
spectrum of action; the other was strain-specific. This suggests that the
spectrum of action of not only certain HA-specific antibodies, but also
antibodies to other influenza antigens exposed on the surface of an infected
cell, depends on the Fc-Fc&#x003b3;R interaction. Moreover, the dependence of some
antibodies on the Fc-Fc&#x003b3;R interaction can be circumvented by significantly
(8&#x02013;10-fold) increasing the amount of the antibody involved in the
interaction with the influenza virus. It should be noted that, during viral
infection, broad-spectrum antibodies are generated in much smaller quantities
than strain-specific ones. Thus, the Fc-Fc&#x003b3;R interaction apparently can
increase the efficiency of the broad-spectrum antibodies, thereby compensating
for their small quantity [<xref rid="R16" ref-type="bibr">16</xref>].
</p><p>
Antibodies to conserved viral proteins, such as nucleoprotein (NP), also
contribute to the ADCC response. For instance, the influenza infection and
vaccination induce the production of antibodies to the NP, M1, and M2 proteins
involved in ADCC [<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R18" ref-type="bibr">18</xref>]. It has been shown that influenza virus NP
is expressed on the surface of infected cells for some time and, therefore, can
serve as a target for ADCC [<xref rid="R19" ref-type="bibr">19</xref>-<xref rid="R21" ref-type="bibr">21</xref>]. Carragher et al. demonstrated that
vaccination of laboratory mice with soluble recombinant NP of the influenza A
virus induces high titers of antibodies to NP and an extremely weak T cell
response. At the same time, vaccination reduced the manifestation of disease
symptoms and decreased the influenza virus titers in the lungs of the
influenza-infected animals infected. Passive transfer of the sera of immunized
mice to naive animals also provided protection against an influenza infection
[<xref rid="R22" ref-type="bibr">22</xref>]. Subsequent studies have
demonstrated that the protective effects of the serum of mice immunized with
influenza A recombinant NP upon passive transfer to animals with B cell
deficiency and mice with a normal number of B cells manifest themselves through
the mechanism that includes Fc&#x003b3;R [<xref rid="R23" ref-type="bibr">23</xref>]. Macaque studies have shown that NP-specific antibodies
have the ability to activate NK cells <italic>in vitro </italic>[<xref rid="R18" ref-type="bibr">18</xref>, <xref rid="R24" ref-type="bibr">24</xref>].
</p><p>
The serum of healthy children and adults (but not infants) contains antibodies
to various proteins of the H7N9 influenza A virus that are involved in the ADCC
response, with the level of NP-specific antibodies being significantly higher
than those to HA and NA. The level of antibodies to NP of the seasonal
influenza A viruses that are involved in ADCC correlated with the level of
antibodies to NP of the H7N9 influenza A virus. Therefore, production of these
antibodies that cross-react with H7N9 is assumed to be triggered by vaccination
and infection with seasonal influenza A viruses [<xref rid="R25" ref-type="bibr">25</xref>]. The antibodies to influenza A virus NP involved in ADCC
were found in children vaccinated with seasonal inactivated influenza virus
vaccines. NP-specific antibodies that can interact with Fc&#x003b3;RIIIa and
activate NK cells have been identified in healthy and influenza-infected
volunteers. Healthy donor serum containing NP-specific antibodies were shown to
induce NK cell activation against virus-infected cells expressing NP [<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R26" ref-type="bibr">26</xref>].
</p><p>
Another conserved influenza protein found on the surface of infected cells is
the M2 ion channel. Antibodies to this protein can protect mice from an
influenza virus infection in laboratory experiments. Moreover, in the
immunization of animals with the M2 ectodomain both in soluble form and as
conjugated to various carriers, the protective ability depends mainly on the
antibodies. Notably, the presence of NK cells was critical to protection.
[<xref rid="R27" ref-type="bibr">27</xref>]. Experiments on passive
immunization of both wild-type mice and mice with the FcR&#x003b3;-/-,
Fc&#x003b3;RI-/-, Fc&#x003b3;RIII-/-, and (Fc&#x003b3;RI, Fc&#x003b3;RIII)-/- phenotypes
showed that FcR (more specifically, Fc&#x003b3;RIII) is required for the
protective effect of anti-M2e antibodies [<xref rid="R28" ref-type="bibr">28</xref>, <xref rid="R29" ref-type="bibr">29</xref>]. The human
monoclonal antibody against the influenza A (Ab1-10) virus M2 protein was able
to activate NK cells and trigger ADCC <italic>in vitro</italic>, with ADCC
against both target cells expressing M2 and cells infected with influenza
[<xref rid="R30" ref-type="bibr">30</xref>].
</p><fig id="F3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>
Evaluation of ADCC in the laboratory. (a) Evaluation of ADCC using immobilized
influenza virus antigens. Firstly, antigens are immobilized, washed, and
incubated with serum or IgG isolated from the blood. Secondly, unbound IgGs are
washed off and effector cells (peripheral blood monocytes or isolated NK cells)
are added to the antigen-antibody complex. Thirdly, after incubation,
activation of the effector cells is analyzed. Activation is evaluated by adding
labeled antibodies to the surface and secreted marker proteins (as a rule, the
surface membrane activation marker CD107a and interferon gamma are used). (b)
Evaluation of ADCC using influenza virus-infected cells or target cells
expressing the major viral antigens. Cells expressing viral antigens are
incubated with serum or preliminarily purified IgG. Next, effector cells are
added to the antibody-treated cells and ADCC is evaluated by counting dead
target antibody-treated cells
</p></caption><graphic xlink:href="AN20758251-11-04-022-g003"/></fig><p>
To accurately determine the level of anti-influenza antibodies involved in
ADCC, a reaction with the participation of the target antigen and effector
cells (usually NK cells) is required. The antigen can be either a recombinant
target protein, influenza-infected cells, or target cells expressing the
desired antigens. If the antigen is a recombinant protein, it is treated with
the test serum and then effector cells are added to the resulting
antigen&#x02013;antibody complex. When conducting this reaction, one can assess
ADCC by measuring the activation of the effector cells and their expression of
surface and secreted marker proteins (as a rule, these are surface activation
marker CD107a and interferon
gamma) <italic>(<xref ref-type="fig" rid="F3">Fig. 3, a</xref>)</italic>
[<xref rid="R31" ref-type="bibr">31</xref>]. If the antigen is infected cells or
target cells, ADCC can also be analyzed by assessing the death rate of
antibody-treated target cells after their interaction with effector
cells <italic>(<xref ref-type="fig" rid="F3">Fig. 3, b</xref>)</italic>
[<xref rid="R32" ref-type="bibr">32</xref>].
</p><p>
<bold>Antibody-dependent cellular phagocytosis (ADCP)</bold>
</p><p>
Phagocytosis is a crucial immunological process in which phagocytes engulf
microbial and infected cells. The first step of ADCP includes opsonization of a
microbial or infected cell by antibodies. After opsonization, phagocytes
recognize the antibodies bound to foreign antigens, mainly via the Fc&#x003b3;
receptors CD32 (Fc&#x003b3;RIIA) and CD64 (Fc&#x003b3;RIA), as well as the Fc&#x003b1;
receptor CD89 [<xref rid="R33" ref-type="bibr">33</xref>]. The phagocytes
involved in ADCP include monocytes, macrophages, neutrophils, and dendritic
cells <italic>(<xref ref-type="fig" rid="F4">Fig. 4</xref>)</italic>
[<xref rid="R17" ref-type="bibr">17</xref>,
<xref rid="R34" ref-type="bibr">34</xref>]. ADCP is one of the most important
antibody-induced effector defense mechanisms against the influenza virus.
Fc&#x003b3;R-/- mice have been shown to be highly sensitive to influenza even in
the presence of influenza antibodies obtained from Fc&#x003b3;R+/+ mice. Moreover,
the absence of NK cells was not crucial for the defense response. It has also
been shown that Fc&#x003b3;R+/+ mouse macrophages actively engulf opsonized viral
particles [<xref rid="R35" ref-type="bibr">35</xref>]. Dunand et al. showed
that some non-neutralizing human broad-spectrum monoclonal antibodies protect
mice from an influenza infection through Fc-mediated recruitment of effector
cells, with the protection being associated exclusively with ADCP but not with
ADCC or activation of the complement system [<xref rid="R36" ref-type="bibr">36</xref>].
</p><fig id="F4" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>
The mechanism of the protective action of the antibodies binding to the
ectodomain of the influenza M2 ion channel. Respiratory tract epithelial cells
infected with the influenza A virus expose the HA, NA, and M2 viral proteins on
their surface. New viral particles are budding from the infected cells. On the
surface of the budding virion, antibodies bind to the ectodomain of the M2
protein and opsonize the viral particle. These antibodies activate alveolar
macrophages via Fc&#x003b3; receptors. Activated macrophages are able to
phagocytize budding virions and fragments of the cell membrane containing the
M2 protein. Dying infected cells can be also opsonized by antibodies to the M2
ectodomain and phagocytosed by alveolar macrophages via the Fc&#x003b3;R-dependent
pathway. Activated macrophages also produce type I interferons, which possess
antiviral activity and regulate the expression of chemokine CCL2, which
attracts bone marrow macrophages promoting tissue repair
</p></caption><graphic xlink:href="AN20758251-11-04-022-g004"/></fig><p>
According to He et al., alveolar macrophages are crucial for the induction of
ADCP by human and mouse monoclonal antibodies both <italic>in vitro
</italic>and in experiments on protecting animals from infection with
homologous and heterologous influenza A virus strains
[<xref rid="R37" ref-type="bibr">37</xref>]. Interestingly, the ability of alveolar
macrophages to protect the lungs from damage during an influenza infection is reduced in
elderly mice [<xref rid="R38" ref-type="bibr">38</xref>].
</p><p>
In addition to alveolar macrophages, other effector cell populations can also
participate in the ADCP-mediated response to the influenza virus. For instance,
neutrophils, which are the largest in number amongst blood leukocytes, express
high levels of Fc&#x003b3;RIa/b/c, Fc&#x003b3;RIIa, and Fc&#x003b3;RIIIb on their
surface after activation. In addition, neutrophils constitutively express
Fc&#x003b1;RI, which binds IgA and activates the cytotoxic and phagocytic
responses [<xref rid="R15" ref-type="bibr">15</xref>]. Analysis of the
Fc-Fc&#x003b3;R interactions between various IgG specific to the HA stem and
effector neutrophils showed that monoclonal human and mouse HA stem-specific
antibodies can induce the production of reactive oxygen species (ROS), which
are further delivered to the neutrophil`s phagolysosomes. However, such an
effect could not be detected in the case of HA head-specific antibodies [<xref rid="R39" ref-type="bibr">39</xref>]. The depletion of neutrophils resulted in
a reduced survival rate of influenza-infected mice [<xref rid="R40" ref-type="bibr">40</xref>, <xref rid="R41" ref-type="bibr">41</xref>].
</p><p>
A study of the ADCP mechanism in the influenza infection showed that both
macrophages and neutrophils are quickly recruited to the lungs and are present
in bronchoalveolar lavage, the respiratory tract, and alveoli, where they
contribute to the rapid scavenging of infected and dead cells. Although the
supernatant of influenza-infected cells can stimulate phagocytosis by monocytes
regardless of the involvement of antibodies [<xref rid="R40" ref-type="bibr">40</xref>], antibodies contribute to the effective clearance of viral
particles and infected cells by interacting with the Fc&#x003b3;RIa and
Fc&#x003b3;RIIa on immune cells. Antibody-mediated viral phagocytosis causes a
decrease in the infection spread and severity, as well as it symptoms, and a
reduction in virus shedding [<xref rid="R42" ref-type="bibr">42</xref>]. It is
assumed that each subsequent influenza infection, as well as influenza
vaccinations, slightly induces the cross-reactive antibodies involved in ADCP,
with their level increasing with each subsequent influenza infection [<xref rid="R17" ref-type="bibr">17</xref>].
</p><p>
Various anti-influenza antibodies, including antibodies to the hemagglutinin
stem [<xref rid="R36" ref-type="bibr">36</xref>, <xref rid="R37" ref-type="bibr">37</xref>, <xref rid="R39" ref-type="bibr">39</xref>] and antibodies
to the M2 ion channel [<xref rid="R28" ref-type="bibr">28</xref>, <xref rid="R43" ref-type="bibr">43</xref>], can induce ADCP.
</p><p>
The activity of the antibodies responsible for ADCP is studied as follows:
target cells expressing influenza antigens are labeled with an intravital dye,
then the target antibodies and phagocytic cells are added, and the survival
number of the target cells is assessed. [<xref rid="R35" ref-type="bibr">35</xref>].
</p><p>
<bold>Antibody-mediated complement-dependent cytotoxicity (CDC)</bold>
</p><p>
The complement system consists of soluble and membrane-bound proteins that are
found in the blood and tissues of mammals. These proteins interact with each
other and with other components of the immune system, resulting in the
production of a number of effector proteins that contribute to the elimination
of various pathogens [<xref rid="R27" ref-type="bibr">27</xref>].
</p><p>
As early as in 1978, it was shown that the complement system is necessary to
protect mice from a lethal influenza infection [<xref rid="R44" ref-type="bibr">44</xref>]. In 1983, it was established that human serum contains
antibodies capable of neutralizing the influenza virus by activating the
classical complement pathway [<xref rid="R45" ref-type="bibr">45</xref>]. To
date it is known that influenza virions can activate both the classical and
alternative complement pathways, and that antibody opsonization is required for
efficient lysis of virions [<xref rid="R46" ref-type="bibr">46</xref>].
</p><p>
In 2018, research was carried out to study the effectiveness of immunization of
mice with a knockout of the C3 complement component with virus-like particles
carrying the M2e proteins of human, porcine, and avian influenza A viruses, as
well as virus-like particles carrying HA of the H5-subtype influenza A virus.
It turned out that immunization with the M2e vaccine did not protect C3
knockout mice from the influenza A viruses, while even low levels of antibodies
to the M2e protein were enough to protect wild-type animals from the influenza
A virus infection upon passive transfer. On the contrary, C3 knockout mice
immunized with a HA vaccine, which induces the production of strain-specific
neutralizing antibodies, were protected from infection with a homologous
influenza virus despite the low level of antibody response [<xref rid="R47" ref-type="bibr">47</xref>]. Thus, one can state the ability of
antibodies to the influenza virus M2 ion channel to protect against influenza A
virus infection through the activation of the complement system.
</p><p>
The complement system is not only capable of neutralizing viral particles, but
it is also involved in the lysis of infected cells. For instance, vaccination
with a seasonal trivalent inactivated influenza vaccine led to an increase in
the level of antibodies capable of activating the complement-dependent lysis of
influenza-infected cells <italic>in vitro</italic>, although the effect was not
pronounced [<xref rid="R48" ref-type="bibr">48</xref>]. CDC-inducing antibodies
were detected among both influenza HA head-specific and stem-specific
antibodies. Meanwhile, antibodies to the stem domain demonstrated a broad
spectrum of action and were able to induce CDC against different influenza A
strains [<xref rid="R49" ref-type="bibr">49</xref>].
</p><p>
Antibodies of the IgG1 and IgM classes have been shown to be involved in the
activation of the complement system [<xref rid="R46" ref-type="bibr">46</xref>]. The level of antibodies involved in CDC correlated with
the protection against a seasonal influenza virus in children [<xref rid="R32" ref-type="bibr">32</xref>].
</p><p>
The activity of antibodies in CDC is evaluated by the rate of death of target
cells expressing the influenza antigen or infected with an influenza virus in
solutions containing complement components and antibodies. Cell death is
assessed using various metabolic dyes [<xref rid="R50" ref-type="bibr">50</xref>].
</p></sec><sec><title>ANTIBODIES TO INFLUENZA VIRUS HEMAGGLUTININ AND NEURAMINIDASE</title><p>
Influenza virus HA and NA are highly variable proteins. However, the
broad-spectrum vaccines that are currently under development may also include
HA and/or NA and their epitopes. For instance, the HA stem is a rather
conserved part of the molecule. Various strategies exist for redirection of the
immune response to this particular antigen during vaccination [<xref rid="R51" ref-type="bibr">51</xref>]. Most NA-specific monoclonal antibodies
obtained from the serum of people who have been infected bind to different
influenza strains, providing ground for the development of broad-spectrum
vaccines based on this antigen [<xref rid="R52" ref-type="bibr">52</xref>].
</p><p>
<bold>Antibodies to the influenza virus HA stem</bold>
</p><p>
The HA stem is more conserved than the head domain. However, it is less
immunogenic, possibly due to the fact that the bulky head region of the protein
sterically hinders the access of antibodies to the HA stem. However, in
addition to the non-neutralizing antibodies involved in the ADCC, ADCP, and CDC
reactions, a certain amount of neutralizing HA stem-specific antibodies is
detected in humans after an influenza infection or vaccination, with the
infection being more effective in inducing the formation of this type of
antibodies than vaccination.
</p><p>
HA stem-specific antibodies can interfere with the fusion of the virus with the
endosomal membrane. Effective fusion requires the presence of 3&#x02013;5
neighboring HAs with fusion peptides bound to the endosomal membrane
<italic>(<xref ref-type="fig" rid="F1">Fig. 1, c</xref>)</italic>.
Neutralizing HA stem-specific are able to prevent
the pH-induced exposure of the fusion peptide and prevent the formation of a
network of HAs interacting with the endosomal membrane. In addition, some
antibodies to the HA stem can inhibit cleavage of the immature HA0 precursor
into the HA1 and HA2
subunits <italic>(<xref ref-type="fig" rid="F1">Fig. 1, e</xref>)</italic>,
which are required
for a successful infection of cells with a newly formed viral particle
[<xref rid="R4" ref-type="bibr">4</xref>]. HA
stem-specific antibodies can suppress the release of viral particles from the
cell <italic>(<xref ref-type="fig" rid="F1">Fig. 1, d</xref>)</italic>
[<xref rid="R53" ref-type="bibr">53</xref>], including the pathway involving steric
inhibition of neuraminidase activity [<xref rid="R54" ref-type="bibr">54</xref>].
</p><p>
Neutralizing HA stem-specific antibodies cannot be revealed using a
hemagglutination assay. The principal methods for an evaluation of these
antibodies are the reactions of neutralization
[<xref rid="R5" ref-type="bibr">5</xref>], microneutralization
[<xref rid="R6" ref-type="bibr">6</xref>], and neutralization based on
pseudotyped viral vectors
[<xref rid="R55" ref-type="bibr">55</xref>]. The latter present chimeric
viruses carrying influenza virus surface antigens that do not contain any
genetic material and are not infectious. These pseudoviruses are usually
derived from lentiviral vectors and the vesicular stomatitis virus. They allow
avoidance of highly pathogenic influenza strains when performing a
neutralization reaction (which is especially important when studying
broad-spectrum antibodies). According to some reports, this method of
evaluation is more sensitive and more suitable in the detection of neutralizing
HA stem-specific antibodies than the conventional neutralization assay
[<xref rid="R55" ref-type="bibr">55</xref>].
</p><p>
<bold>Antibodies to influenza virus neuraminidase</bold>
</p><p>
Influenza virus neuraminidase is involved in various stages of the infectious
process. It cleaves the viral particles from the sialic acid residues of the
respiratory tract mucins, thus allowing for the virus entry into the cell. NA
allows the release of new virions from the host cell, thus preventing them from
remaining bound to the sialic acid residues on the cell surface. In addition,
NA prevents the aggregation of virions, which is due to the interaction between
the HA of a virion with the sialylated glycans of another one
[<xref rid="R56" ref-type="bibr">56</xref>]. Antibodies to the influenza
virus NA can interfere with any of these
processes <italic>(<xref ref-type="fig" rid="F1">Fig. 1, a,d</xref>)</italic>.
</p><p>
It was shown that, in the absence of HA-specific antibodies, NA-specific
antibodies can protect laboratory animals from an influenza infection [57].
Moreover, the presence of NA-specific antibodies also correlates with
protection against an influenza virus in humans. The titer of anti-NA antibody
has been shown to increase in human blood with age
[<xref rid="R56" ref-type="bibr">56</xref>].
</p><p>
The production of antibodies to neuraminidase is induced by an influenza
infection. However, their level is usually lower than that of the antibodies to
HA. It is crucial that most NA-specific monoclonal antibodies derived from the
serum of individuals who have suffered from an infection bind to a wide range
of modern and historical influenza strains, inhibit NA activity, and protect
laboratory mice in passive transfer experiments
[<xref rid="R52" ref-type="bibr">52</xref>]. Several strategies for the development of broad-spectrum
vaccines that induce the formation of antibodies to influenza NA exist. One of
them is the creation of a pandemic vaccine based on a cocktail of several
subtypes of NA (N1, N2, N6, N7, N8, N9, and etc.) associated with human and
zoonotic influenza strains. It is also possible to include NA as an additional
antigen in vaccines based on conserved influenza antigens: such as M2, NP, etc.
[<xref rid="R58" ref-type="bibr">58</xref>].
</p><p>
ELISA is one of the easiest ways to evaluate the immune response to NA. To
reliably assess the level of NA-specific antibodies, recombinant, tetrameric,
glycosylated, and enzymatically active NA should be used as antigen. However,
ELISA does not provide any information on the functionality of the measured
level of antibodies. NA enzymatic activity inhibition assays are based on the
cleavage of small molecules by neuraminidase, which generates the signal to be
measured. However, unlike terminal sialic acids, which are attached to the
glycans of large proteins, these small molecules more easily access the active
center of the NA protein [<xref rid="R59" ref-type="bibr">59</xref>]. The assay
that allows one to obtain the most realistic estimates of the anti-NA activity
of antibodies is ELLA (enzyme-linked lectin assay), which uses the highly
sialylated glycoprotein fetuin as a substrate. The method is based on measuring
the amount of galactose, the penultimate sugar residue in fetuin, which is
bound to the substrate. NA cleaves terminal sialic acids, after which galactose
can be measured using horseradish peroxidase-conjugated peanut lectin. ELLA has
been optimized for routine serology; it is now used to evaluate the titers of
neuraminidase-inhibiting antibodies [<xref rid="R58" ref-type="bibr">58</xref>].
</p><p>
A key component of ELLA is enzymatically active NA, the inhibition of which is
evaluated. NA can be used in the form of a purified protein or as part of a
viral particle. When using a viral particle, it should be kept in mind that
HA-binding antibodies can reduce NA activity due to the steric hindrance
effect. Therefore, reassortant viruses of the H6NX and H7NX subtypes are
commonly used in this assay. Although the use of reassortant viruses cannot
completely exclude the effect of HA-specific antibodies on the NA activity,
this assay is considered as the "gold" standard in the evaluation of the
inhibitory anti-NA activity of antibodies [<xref rid="R59" ref-type="bibr">59</xref>].
</p></sec><sec><title>CONCLUSIONS</title><p>
In this review, the main mechanisms involving anti-influenza antibodies and the
methods for the detection of these antibodies were considered. Antibodies can
provide protection against influenza via Fc-independent or Fc-dependent
mechanisms. Fc-independent antibodies directly neutralize the virus by
preventing its entry into the cell, fusion, or budding from it. Antibodies to
the head domain of hemagglutinin [<xref rid="R5" ref-type="bibr">5</xref>],
which are usually strain-specific, are mainly involved in the direct
neutralization of the influenza virus. As a rule, Fc-dependent antibodies are
non-neutralizing but are able to activate antibody-dependent cellular
cytotoxicity, antibody-dependent cellular phagocytosis, or the complement
system [<xref rid="R18" ref-type="bibr">18</xref>, <xref rid="R34" ref-type="bibr">34</xref>, <xref rid="R49" ref-type="bibr">49</xref>]. Such
antibodies can be targeted at the stem domain of the HA, NA, M2, or NP proteins
of the influenza virus, and most of them are broad-spectrum antibodies [<xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R21" ref-type="bibr">21</xref>,
<xref rid="R28" ref-type="bibr">28</xref>, <xref rid="R58" ref-type="bibr">58</xref>].
</p><p>
The influenza vaccines currently being developed are aimed at generating an
immune response not mainly to the conventional HA and NA influenza antigens,
but to various conserved viral antigens. When creating a broad-spectrum
vaccine, it is necessary to know what effectiveness criteria should be
considered in preclinical and clinical trials. The traditional methods for
assessing the humoral immune response to influenza vaccines by hemagglutination
and neutralization reactions will no longer be relevant for most newly
developed vaccines. The development of methods for evaluating non-neutralizing
anti-influenza antibodies and studying their mechanisms of action are necessary
if we seek to create effective broad-spectrum vaccines that can provide
protection against both seasonal and potentially pandemic influenza virus
strains.
</p></sec></body><back><glossary><def-list><title>Abbreviations</title><def-item><term id="G01">ADCC</term><def><p>antibody-dependent cellular cytotoxicity</p></def></def-item><def-item><term id="G02">ADCP</term><def><p>antibody-dependent cellular phagocytosis</p></def></def-item><def-item><term id="G03">CDC</term><def><p>antibody-mediated complement-dependent cytotoxicity</p></def></def-item><def-item><term id="G04">HA</term><def><p>hemagglutinin</p></def></def-item><def-item><term id="G05">NA</term><def><p>neuraminidase</p></def></def-item><def-item><term id="G06">NP</term><def><p>nucleoprotein</p></def></def-item><def-item><term id="G07">WHO</term><def><p>World Health Organization</p></def></def-item><def-item><term id="G08">DNA</term><def><p>deoxyribonucleic acid</p></def></def-item><def-item><term id="G09">NK</term><def><p>natural killers</p></def></def-item><def-item><term id="G10">ITAM</term><def><p>immunoreceptor tyrosine-based activation motif</p></def></def-item><def-item><term id="G11">ELISA</term><def><p>enzyme-linked immunosorbent assay</p></def></def-item><def-item><term id="G12">IFN&#x003b3;</term><def><p>interferon gamma</p></def></def-item><def-item><term id="G13">TNF&#x003b1;</term><def><p>tumor necrosis factor alfa</p></def></def-item><def-item><term id="G14">ELLA</term><def><p>enzyme-linked lectin assay</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><source>Lancet.</source><year>2017</year><volume>390</volume><fpage>697</fpage><lpage>708</lpage><name><surname>Paules</surname><given-names>C.</given-names></name><name><surname>Subbarao</surname><given-names>K.</given-names></name><pub-id pub-id-type="pmid">28302313</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><source>Acta Naturae.</source><year>2012</year><volume>4</volume><issue>4</issue><fpage>17</fpage><lpage>27</lpage><name><surname>Sedova</surname><given-names>E.S.</given-names></name><name><surname>Shcherbinin</surname><given-names>D.N.</given-names></name><name><surname>Migunov</surname><given-names>A.I.</given-names></name><name><surname>Smirnov</surname><given-names>Iu.A.</given-names></name><name><surname>Logunov</surname><given-names>D.Iu.</given-names></name><name><surname>Shmarov</surname><given-names>M.M.</given-names></name><name><surname>Tsybalova</surname><given-names>L.M.</given-names></name><name><surname>Naroditski&#x000ee;</surname><given-names>B.S.</given-names></name><name><surname>Kiselev</surname><given-names>O.I.</given-names></name><name><surname>Gintsburg</surname><given-names>A.L.</given-names></name><pub-id pub-id-type="pmid">23346377</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><source>Nat. Rev. Immunol.</source><year>2019</year><volume>19</volume><issue>6</issue><fpage>383</fpage><lpage>397</lpage><name><surname>Krammer</surname><given-names>F.</given-names></name><pub-id pub-id-type="pmid">30837674</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><source>Acta Naturae.</source><year>2016</year><volume>8</volume><issue>1</issue><fpage>13</fpage><lpage>20</lpage><name><surname>Shcherbinin</surname><given-names>D.N.</given-names></name><name><surname>Alekseeva</surname><given-names>S.V.</given-names></name><name><surname>Shmarov</surname><given-names>M.M.</given-names></name><name><surname>Smirnov</surname><given-names>Y.A.</given-names></name><name><surname>Naroditskiy</surname><given-names>B.S.</given-names></name><name><surname>Gintsburg</surname><given-names>A.L.</given-names></name><pub-id pub-id-type="pmid">27099781</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><source>Influenza Other Respi. Viruses.</source><year>2016</year><volume>10</volume><fpage>518</fpage><lpage>524</lpage><name><surname>Truelove</surname><given-names>S.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Lessler</surname><given-names>J.</given-names></name><name><surname>Riley</surname><given-names>S.</given-names></name><name><surname>Read</surname><given-names>J.M.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Kwok</surname><given-names>K.O.</given-names></name><name><surname>Guan</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>C.Q.</given-names></name><name><surname>Cummings</surname><given-names>D.A.</given-names></name></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><source>Meth. Mol. Biol.</source><year>2014</year><volume>1161</volume><fpage>325</fpage><lpage>335</lpage><name><surname>Kitikoon</surname><given-names>P.</given-names></name><name><surname>Vincent</surname><given-names>A.L.</given-names></name></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><source>PLoS One.</source><year>2013</year><volume>8</volume><issue>12</issue><elocation-id>e80034</elocation-id><name><surname>Brandenburg</surname><given-names>B.</given-names></name><name><surname>Koudstaal</surname><given-names>W.</given-names></name><name><surname>Goudsmit</surname><given-names>J.</given-names></name><name><surname>Klaren</surname><given-names>V.</given-names></name><name><surname>Tang</surname><given-names>Ch.</given-names></name><name><surname>Bujny</surname><given-names>M.V.</given-names></name><name><surname>Korse</surname><given-names>H.J.</given-names></name><name><surname>Kwaks</surname><given-names>T.</given-names></name><name><surname>Otterstrom</surname><given-names>J.J.</given-names></name><name><surname>Juraszek</surname><given-names>J.</given-names></name><pub-id pub-id-type="pmid">24348996</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><source>Nat. Rev. Immunol.</source><year>2018</year><volume>18</volume><fpage>46</fpage><lpage>61</lpage><name><surname>Lu</surname><given-names>L.L.</given-names></name><name><surname>Suscovich</surname><given-names>T.J.</given-names></name><name><surname>Fortune</surname><given-names>S.M.</given-names></name><name><surname>Alter</surname><given-names>G.</given-names></name><pub-id pub-id-type="pmid">29063907</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><source>Immunol. Rev.</source><year>2015</year><volume>268</volume><issue>1</issue><fpage>25</fpage><lpage>51</lpage><name><surname>Bruhns</surname><given-names>P.</given-names></name><name><surname>J&#x000f6;nsson</surname><given-names>F.</given-names></name><pub-id pub-id-type="pmid">26497511</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><source>Curr. Opin. Virol.</source><year>2017</year><volume>22</volume><fpage>89</fpage><lpage>96</lpage><name><surname>Vanderven</surname><given-names>H.A.</given-names></name><name><surname>Jegaskanda</surname><given-names>S.</given-names></name><name><surname>Wheatley</surname><given-names>A.K.</given-names></name><name><surname>Kent</surname><given-names>S.J.</given-names></name><pub-id pub-id-type="pmid">28088123</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><source>Nat. Med.</source><year>2014</year><volume>20</volume><fpage>143</fpage><lpage>151</lpage><name><surname>DiLillo</surname><given-names>D.J.</given-names></name><name><surname>Tan</surname><given-names>G.S.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name><name><surname>Ravetch</surname><given-names>J.V.</given-names></name><pub-id pub-id-type="pmid">24412922</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><source>Virology Journal</source><year>2013</year><volume>87</volume><fpage>5512</fpage><lpage>5522</lpage><name><surname>Jegaskanda</surname><given-names>S.</given-names></name><name><surname>Weinfurter</surname><given-names>J.T.</given-names></name><name><surname>Friedrich</surname><given-names>T.C.</given-names></name><name><surname>Kent</surname><given-names>S.J.</given-names></name></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><source>J. Infect. Dis.</source><year>2016</year><volume>214</volume><fpage>945</fpage><lpage>952</lpage><name><surname>Jegaskanda</surname><given-names>S.</given-names></name><name><surname>Luke</surname><given-names>C.</given-names></name><name><surname>Hickman</surname><given-names>H.D.</given-names></name><name><surname>Sangster</surname><given-names>M.Y.</given-names></name><name><surname>Wieland-Alter</surname><given-names>W.F.</given-names></name><name><surname>McBride</surname><given-names>J.M.</given-names></name><name><surname>Yewdell</surname><given-names>J.W.</given-names></name><name><surname>Wright</surname><given-names>P.F.</given-names></name><name><surname>Treanor</surname><given-names>J.</given-names></name><name><surname>Rosenberger</surname><given-names>C.M.</given-names></name><pub-id pub-id-type="pmid">27354365</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><source>J. Infect. Dis.</source><year>2013</year><volume>208</volume><fpage>1051</fpage><lpage>1061</lpage><name><surname>Jegaskanda</surname><given-names>S.</given-names></name><name><surname>Laurie</surname><given-names>K.L.</given-names></name><name><surname>Amarasena</surname><given-names>T.H.</given-names></name><name><surname>Winnall</surname><given-names>W.R.</given-names></name><name><surname>Kramski</surname><given-names>M.</given-names></name><name><surname>De Rose</surname><given-names>R.</given-names></name><name><surname>Barr</surname><given-names>I.G.</given-names></name><name><surname>Brooks</surname><given-names>A.G.</given-names></name><name><surname>Reading</surname><given-names>P.C.</given-names></name><name><surname>Kent</surname><given-names>S.J.</given-names></name><pub-id pub-id-type="pmid">23812238</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>440</fpage><name><surname>Boudreau</surname><given-names>C.M.</given-names></name><name><surname>Alter</surname><given-names>G.</given-names></name><pub-id pub-id-type="pmid">30949165</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><source>J. Clin. Invest.</source><year>2016</year><volume>126</volume><fpage>605</fpage><lpage>610</lpage><name><surname>DiLillo</surname><given-names>D.J.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name><name><surname>Wilson</surname><given-names>P.C.</given-names></name><name><surname>Ravetch</surname><given-names>J.V.</given-names></name><pub-id pub-id-type="pmid">26731473</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><source>Expert. Rev. Vaccines.</source><year>2018</year><volume>17</volume><issue>9</issue><fpage>785</fpage><lpage>795</lpage><name><surname>Sicca</surname><given-names>F.</given-names></name><name><surname>Neppelenbroek</surname><given-names>S.</given-names></name><name><surname>Huckriede</surname><given-names>A.</given-names></name><pub-id pub-id-type="pmid">30145912</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><source>J. Immunol.</source><year>2014</year><volume>193</volume><issue>2</issue><fpage>469</fpage><lpage>475</lpage><name><surname>Jegaskanda</surname><given-names>S.</given-names></name><name><surname>Reading</surname><given-names>P.C.</given-names></name><name><surname>Kent</surname><given-names>S.J.</given-names></name><pub-id pub-id-type="pmid">24994909</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><source>Nature</source><year>1977</year><volume>266</volume><fpage>52</fpage><lpage>54</lpage><name><surname>Virelizier</surname><given-names>J.L.</given-names></name><name><surname>Allison</surname><given-names>A.C.</given-names></name><name><surname>Oxford</surname><given-names>J.S.</given-names></name><name><surname>Schild</surname><given-names>G.C.</given-names></name><pub-id pub-id-type="pmid">840296</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><source>J. Immunol.</source><year>1981</year><volume>126</volume><fpage>1814</fpage><lpage>1819</lpage><name><surname>Yewdell</surname><given-names>J.W.</given-names></name><name><surname>Frank</surname><given-names>E.</given-names></name><name><surname>Gerhard</surname><given-names>W.</given-names></name><pub-id pub-id-type="pmid">7217668</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><source>Clin. Vaccine Immunol.</source><year>2013</year><volume>20</volume><fpage>1333</fpage><lpage>1337</lpage><name><surname>Bodewes</surname><given-names>R.</given-names></name><name><surname>Geelhoed-Mieras</surname><given-names>M.M.</given-names></name><name><surname>Wrammert</surname><given-names>J.</given-names></name><name><surname>Ahmed</surname><given-names>R.</given-names></name><name><surname>Wilson</surname><given-names>P.C.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>Rimmelzwaan</surname><given-names>G.F.</given-names></name><pub-id pub-id-type="pmid">23761662</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><source>J. Immunol.</source><year>2008</year><volume>181</volume><fpage>4168</fpage><lpage>4176</lpage><name><surname>Carragher</surname><given-names>D.M.</given-names></name><name><surname>Kaminski</surname><given-names>D.A.</given-names></name><name><surname>Moquin</surname><given-names>A.</given-names></name><name><surname>Hartson</surname><given-names>L.</given-names></name><name><surname>Randall</surname><given-names>T.D.</given-names></name><pub-id pub-id-type="pmid">18768874</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><source>J. Immunol.</source><year>2011</year><volume>186</volume><issue>7</issue><fpage>4331</fpage><lpage>4339</lpage><name><surname>LaMere</surname><given-names>M.W.</given-names></name><name><surname>Lam</surname><given-names>H.T.</given-names></name><name><surname>Moquin</surname><given-names>A.</given-names></name><name><surname>Haynes</surname><given-names>L.</given-names></name><name><surname>Lund</surname><given-names>F.E.</given-names></name><name><surname>Randall</surname><given-names>T.D.</given-names></name><name><surname>Kaminski</surname><given-names>D.A.</given-names></name><pub-id pub-id-type="pmid">21357542</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><source>Virology Journal</source><year>2013</year><volume>87</volume><fpage>13706</fpage><lpage>13718</lpage><name><surname>Jegaskanda</surname><given-names>S.</given-names></name><name><surname>Amarasena</surname><given-names>T.H.</given-names></name><name><surname>Laurie</surname><given-names>K.L.</given-names></name><name><surname>Tan</surname><given-names>H.X.</given-names></name><name><surname>Butler</surname><given-names>J.</given-names></name><name><surname>Parsons</surname><given-names>M.S.</given-names></name><name><surname>Alcantara</surname><given-names>S.</given-names></name><name><surname>Petravic</surname><given-names>J.</given-names></name><name><surname>Davenport</surname><given-names>M.P.</given-names></name><name><surname>Hurt</surname><given-names>A.C.</given-names></name></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><source>J. Infect. Dis.</source><year>2017</year><volume>215</volume><issue>5</issue><fpage>818</fpage><lpage>823</lpage><name><surname>Jegaskanda</surname><given-names>S.</given-names></name><name><surname>Co</surname><given-names>M.D.T.</given-names></name><name><surname>Cruz</surname><given-names>J.</given-names></name><name><surname>Subbarao</surname><given-names>K.</given-names></name><name><surname>Ennis</surname><given-names>F.A.</given-names></name><name><surname>Terajima</surname><given-names>M.</given-names></name><pub-id pub-id-type="pmid">28011910</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><source>EBioMedicine.</source><year>2016</year><volume>8</volume><fpage>277</fpage><lpage>290</lpage><name><surname>Vanderven</surname><given-names>H.A.</given-names></name><name><surname>Ana-Sosa-Batiz</surname><given-names>F.</given-names></name><name><surname>Jegaskanda</surname><given-names>S.</given-names></name><name><surname>Rockman</surname><given-names>S.</given-names></name><name><surname>Laurie</surname><given-names>K.</given-names></name><name><surname>Barr</surname><given-names>I.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Wines</surname><given-names>B.</given-names></name><name><surname>Hogarth</surname><given-names>P.M.</given-names></name><name><surname>Lambe</surname><given-names>T.</given-names></name><pub-id pub-id-type="pmid">27428437</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><source>J. Immunol.</source><year>2004</year><volume>172</volume><issue>9</issue><fpage>5598</fpage><lpage>5605</lpage><name><surname>Jegerlehner</surname><given-names>A.</given-names></name><name><surname>Schmitz</surname><given-names>N.</given-names></name><name><surname>Storni</surname><given-names>T.</given-names></name><name><surname>Bachmann</surname><given-names>M.F.</given-names></name><pub-id pub-id-type="pmid">15100303</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><source>J. Immunol.</source><year>2011</year><volume>186</volume><issue>2</issue><fpage>1022</fpage><lpage>1031</lpage><name><surname>El+Bakkouri</surname><given-names>K.</given-names></name><name><surname>Descamps</surname><given-names>F.</given-names></name><name><surname>De+Filette</surname><given-names>M.</given-names></name><name><surname>Smet</surname><given-names>A.</given-names></name><name><surname>Festjens</surname><given-names>E.</given-names></name><name><surname>Birkett</surname><given-names>A.</given-names></name><name><surname>van+Rooijen</surname><given-names>N.</given-names></name><name><surname>Verbeek</surname><given-names>S.</given-names></name><name><surname>Fiers</surname><given-names>W.</given-names></name><name><surname>Saelens</surname><given-names>X.</given-names></name><name><surname>et</surname><given-names>al.</given-names></name><pub-id pub-id-type="pmid">21169548</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><source>Immunology.</source><year>2014</year><volume>143</volume><issue>2</issue><fpage>300</fpage><lpage>309</lpage><name><surname>Lee</surname><given-names>Y.N.</given-names></name><name><surname>Lee</surname><given-names>Y.T.</given-names></name><name><surname>Kim</surname><given-names>M.C.</given-names></name><name><surname>Hwang</surname><given-names>H.S.</given-names></name><name><surname>Lee</surname><given-names>J.S.</given-names></name><name><surname>Kim</surname><given-names>K.H.</given-names></name><name><surname>Kang</surname><given-names>S.M.</given-names></name><pub-id pub-id-type="pmid">24773389</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><source>PLoS One.</source><year>2015</year><volume>10</volume><fpage>1</fpage><lpage>13</lpage><name><surname>Simhadri</surname><given-names>V.R.</given-names></name><name><surname>Dimitrova</surname><given-names>M.</given-names></name><name><surname>Mariano</surname><given-names>J.L.</given-names></name><name><surname>Zenarruzabeitia</surname><given-names>O.</given-names></name><name><surname>Zhong</surname><given-names>W.</given-names></name><name><surname>Ozawa</surname><given-names>T.</given-names></name><name><surname>Muraguchi</surname><given-names>A.</given-names></name><name><surname>Kishi</surname><given-names>H.</given-names></name><name><surname>Eichelberger</surname><given-names>M.C.</given-names></name><name><surname>Borrego</surname><given-names>F.</given-names></name></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><source>J. Immunol.</source><year>2013</year><volume>190</volume><issue>4</issue><fpage>1837</fpage><lpage>1848</lpage><name><surname>Jegaskanda</surname><given-names>S.</given-names></name><name><surname>Job</surname><given-names>E.R.</given-names></name><name><surname>Kramski</surname><given-names>M.</given-names></name><name><surname>Laurie</surname><given-names>K.</given-names></name><name><surname>Isitman</surname><given-names>G.</given-names></name><name><surname>de Rose</surname><given-names>R.</given-names></name><name><surname>Winnall</surname><given-names>W.R.</given-names></name><name><surname>Stratov</surname><given-names>I.</given-names></name><name><surname>Brooks</surname><given-names>A.G.</given-names></name><name><surname>Reading</surname><given-names>P.C.</given-names></name><pub-id pub-id-type="pmid">23319732</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><source>Viral Immunol.</source><year>2014</year><volume>8</volume><fpage>375</fpage><lpage>382</lpage><name><surname>Co</surname><given-names>M.D.</given-names></name><name><surname>Terajima</surname><given-names>M.</given-names></name><name><surname>Thomas</surname><given-names>S.J.</given-names></name><name><surname>Jarman</surname><given-names>R.G.</given-names></name><name><surname>Rungrojcharoenkit</surname><given-names>K.</given-names></name><name><surname>Fernandez</surname><given-names>S.</given-names></name><name><surname>Yoon</surname><given-names>I.K.</given-names></name><name><surname>Buddhari</surname><given-names>D.</given-names></name><name><surname>Cruz</surname><given-names>J.</given-names></name><name><surname>Ennis</surname><given-names>F.A.</given-names></name></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><source>J. Leukoc. Biol.</source><year>2002</year><volume>72</volume><fpage>1092</fpage><lpage>1108</lpage><name><surname>Garc&#x000ed;a-Garc&#x000ed;a</surname><given-names>E.</given-names></name><name><surname>Rosales</surname><given-names>C.</given-names></name><pub-id pub-id-type="pmid">12488490</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><source>Immunol. Rev.</source><year>2014</year><volume>262</volume><fpage>193</fpage><lpage>215</lpage><name><surname>Freeman</surname><given-names>S.A.</given-names></name><name><surname>Grinstein</surname><given-names>S.</given-names></name><pub-id pub-id-type="pmid">25319336</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><source>J. Immunol.</source><year>2001</year><volume>166</volume><fpage>7381</fpage><lpage>7388</lpage><name><surname>Huber</surname><given-names>V.C.</given-names></name><name><surname>Lynch</surname><given-names>J.M.</given-names></name><name><surname>Bucher</surname><given-names>D.J.</given-names></name><name><surname>Le</surname><given-names>J.</given-names></name><name><surname>Metzger</surname><given-names>D.W.</given-names></name><pub-id pub-id-type="pmid">11390489</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><source>Cell Host Microbe.</source><year>2016</year><volume>19</volume><issue>6</issue><fpage>800</fpage><lpage>813</lpage><name><surname>Henry Dunand</surname><given-names>C.J.</given-names></name><name><surname>Leon</surname><given-names>P.E.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Choi</surname><given-names>A.</given-names></name><name><surname>Chromikova</surname><given-names>V.</given-names></name><name><surname>Ho</surname><given-names>I.Y.</given-names></name><name><surname>Tan</surname><given-names>G.S.</given-names></name><name><surname>Cruz</surname><given-names>J.</given-names></name><name><surname>Hirsh</surname><given-names>A.</given-names></name><name><surname>Zheng</surname><given-names>N.Y.</given-names></name><pub-id pub-id-type="pmid">27281570</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><source>Nat. Commun.</source><year>2017</year><volume>8</volume><issue>1</issue><fpage>846</fpage><name><surname>He</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Mullarkey</surname><given-names>C.</given-names></name><name><surname>Hamilton</surname><given-names>J.R.</given-names></name><name><surname>Wong</surname><given-names>C.K.</given-names></name><name><surname>Leon</surname><given-names>P.E.</given-names></name><name><surname>Uccellini</surname><given-names>M.B.</given-names></name><name><surname>Chromikova</surname><given-names>V.</given-names></name><name><surname>Henry</surname><given-names>C.</given-names></name><name><surname>Hoffman</surname><given-names>K.W.</given-names></name><pub-id pub-id-type="pmid">29018261</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><source>J. Immunol.</source><year>2017</year><volume>199</volume><issue>3</issue><fpage>1060</fpage><lpage>1068</lpage><name><surname>Wong</surname><given-names>C.K.</given-names></name><name><surname>Smith</surname><given-names>C.A.</given-names></name><name><surname>Sakamoto</surname><given-names>K.</given-names></name><name><surname>Kaminski</surname><given-names>N.</given-names></name><name><surname>Koff</surname><given-names>J.L.</given-names></name><name><surname>Goldstein</surname><given-names>D.R.</given-names></name><pub-id pub-id-type="pmid">28646038</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><source>MBio.</source><year>2016</year><volume>7</volume><issue>5</issue><fpage>e01624</fpage><lpage>1616</lpage><name><surname>Mullarkey</surname><given-names>C.E.</given-names></name><name><surname>Bailey</surname><given-names>M.J.</given-names></name><name><surname>Golubeva</surname><given-names>D.A.</given-names></name><name><surname>Tan</surname><given-names>G.S.</given-names></name><name><surname>Nachbagauer</surname><given-names>R.</given-names></name><name><surname>He</surname><given-names>W.</given-names></name><name><surname>Novakowski</surname><given-names>K.E.</given-names></name><name><surname>Bowdish</surname><given-names>D.M.</given-names></name><name><surname>Miller</surname><given-names>M.S.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name><pub-id pub-id-type="pmid">27703076</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><source>J. Immunol.</source><year>2007</year><volume>178</volume><issue>4</issue><fpage>2448</fpage><lpage>2457</lpage><name><surname>Hashimoto</surname><given-names>Y.</given-names></name><name><surname>Moki</surname><given-names>T.</given-names></name><name><surname>Takizawa</surname><given-names>T.</given-names></name><name><surname>Shiratsuchi</surname><given-names>A.</given-names></name><name><surname>Nakanishi</surname><given-names>Y.</given-names></name><pub-id pub-id-type="pmid">17277152</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><source>Virology Journal</source><year>2008</year><volume>82</volume><issue>6</issue><fpage>2772</fpage><lpage>2783</lpage><name><surname>Fujisawa</surname><given-names>H.</given-names></name></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><source>PLoS One.</source><year>2016</year><volume>11</volume><fpage>1</fpage><lpage>18</lpage><name><surname>Ana-Sosa-Batiz</surname><given-names>F.</given-names></name><name><surname>Vanderven</surname><given-names>H.</given-names></name><name><surname>Jegaskanda</surname><given-names>S.</given-names></name><name><surname>Johnston</surname><given-names>A.</given-names></name><name><surname>Rockman</surname><given-names>S.</given-names></name><name><surname>Laurie</surname><given-names>K.</given-names></name><name><surname>Barr</surname><given-names>I.</given-names></name><name><surname>Reading</surname><given-names>P.</given-names></name><name><surname>Lichtfuss</surname><given-names>M.</given-names></name><name><surname>Kent</surname><given-names>S.J.</given-names></name></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><source>J. Infect. Dis.</source><year>2019</year><volume>219</volume><issue>1</issue><fpage>S68</fpage><lpage>S74</lpage><name><surname>Saelens</surname><given-names>X.</given-names></name><pub-id pub-id-type="pmid">30715367</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><source>J. Immunol.</source><year>1978</year><volume>121</volume><issue>4</issue><fpage>1437</fpage><lpage>1445</lpage><name><surname>Hicks</surname><given-names>J.T.</given-names></name><name><surname>Ennis</surname><given-names>F.A.</given-names></name><name><surname>Kim</surname><given-names>E.</given-names></name><name><surname>Verbonitz</surname><given-names>M.</given-names></name><pub-id pub-id-type="pmid">701803</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><source>J. Immunol.</source><year>1983</year><volume>130</volume><issue>3</issue><fpage>1317</fpage><lpage>1322</lpage><name><surname>Beebe</surname><given-names>D.P.</given-names></name><name><surname>Schreiber</surname><given-names>R.D.</given-names></name><name><surname>Cooper</surname><given-names>N.R.</given-names></name><pub-id pub-id-type="pmid">6822737</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><source>PLoS Pathog.</source><year>2017</year><volume>13</volume><issue>3</issue><elocation-id>e1006248</elocation-id><name><surname>Rattan</surname><given-names>A.</given-names></name><name><surname>Pawar</surname><given-names>S.D.</given-names></name><name><surname>Nawadkar</surname><given-names>R.</given-names></name><name><surname>Kulkarni</surname><given-names>N.</given-names></name><name><surname>Lal</surname><given-names>G.</given-names></name><name><surname>Mullick</surname><given-names>J.</given-names></name><name><surname>Sahu</surname><given-names>A.</given-names></name><pub-id pub-id-type="pmid">28301559</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><source>Virology Journal</source><year>2018</year><volume>92</volume><issue>20</issue><elocation-id>e00969-18</elocation-id><name><surname>Kim</surname><given-names>Y.J.</given-names></name><name><surname>Kim</surname><given-names>K.H.</given-names></name><name><surname>Ko</surname><given-names>E.J.</given-names></name><name><surname>Kim</surname><given-names>M.C.</given-names></name><name><surname>Lee</surname><given-names>Y.N.</given-names></name><name><surname>Jung</surname><given-names>Y.J.</given-names></name><name><surname>Lee</surname><given-names>Y.T.</given-names></name><name><surname>Kwon</surname><given-names>Y.M.</given-names></name><name><surname>Song</surname><given-names>J.M.</given-names></name><name><surname>Kang</surname><given-names>S.M.</given-names></name></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><source>Hum. Vaccin. Immunother.</source><year>2012</year><volume>8</volume><issue>9</issue><fpage>1218</fpage><lpage>1222</lpage><name><surname>Co</surname><given-names>M.D.</given-names></name><name><surname>Cruz</surname><given-names>J.</given-names></name><name><surname>Takeda</surname><given-names>A.</given-names></name><name><surname>Ennis</surname><given-names>F.A.</given-names></name><name><surname>Terajima</surname><given-names>M.</given-names></name><pub-id pub-id-type="pmid">22894961</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><source>Virology Journal</source><year>2011</year><volume>85</volume><issue>24</issue><fpage>13463</fpage><lpage>13467</lpage><name><surname>Terajima</surname><given-names>M.</given-names></name><name><surname>Cruz</surname><given-names>J.</given-names></name><name><surname>Co</surname><given-names>M.D.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name><name><surname>Kaur</surname><given-names>K.</given-names></name><name><surname>Wrammert</surname><given-names>J.</given-names></name><name><surname>Wilson</surname><given-names>P.C.</given-names></name></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><source>Remedium Journal.</source><year>2016</year><volume>6</volume><fpage>37</fpage><lpage>42</lpage><name><surname>Tuter</surname><given-names>E.A.</given-names></name><name><surname>Poroshin</surname><given-names>G.N.</given-names></name><name><surname>Dranitsyna</surname><given-names>M.A.</given-names></name><name><surname>Vasilyev</surname><given-names>A.N.</given-names></name><name><surname>Niyazov</surname><given-names>R.R.</given-names></name></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><source>Expert Rev. Vaccines.</source><year>2017</year><volume>16</volume><issue>5</issue><fpage>503</fpage><lpage>513</lpage><name><surname>Krammer</surname><given-names>F.</given-names></name><pub-id pub-id-type="pmid">28277797</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><source>Cells.</source><year>2018</year><volume>173</volume><issue>2</issue><fpage>417</fpage><lpage>429</lpage><name><surname>Chen</surname><given-names>Y.Q.</given-names></name><name><surname>Wohlbold</surname><given-names>T.J.</given-names></name><name><surname>Zheng</surname><given-names>N.Y.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Neu</surname><given-names>K.E.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Wan</surname><given-names>H.</given-names></name><name><surname>Rojas</surname><given-names>K.T.</given-names></name><name><surname>Kirkpatrick</surname><given-names>E.</given-names></name></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><source>Virology Journal</source><year>2014</year><volume>88</volume><fpage>13580</fpage><lpage>13592</lpage><name><surname>Tan</surname><given-names>G.S.</given-names></name><name><surname>Lee</surname><given-names>P.S.</given-names></name><name><surname>Hoffman</surname><given-names>R.M.B.</given-names></name><name><surname>Mazel-Sanchez</surname><given-names>B.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name><name><surname>Leon</surname><given-names>P.E.</given-names></name><name><surname>Ward</surname><given-names>A.B.</given-names></name><name><surname>Wilson</surname><given-names>I.A.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><source>J. Exp. Med.</source><year>2019</year><volume>216</volume><issue>2</issue><fpage>304</fpage><lpage>316</lpage><name><surname>Kosik</surname><given-names>I.</given-names></name><name><surname>Angeletti</surname><given-names>D.</given-names></name><name><surname>Gibbs</surname><given-names>J.S.</given-names></name><name><surname>Angel</surname><given-names>M.</given-names></name><name><surname>Takeda</surname><given-names>K.</given-names></name><name><surname>Kosikova</surname><given-names>M.</given-names></name><name><surname>Nair</surname><given-names>V.</given-names></name><name><surname>Hickman</surname><given-names>H.D.</given-names></name><name><surname>Xie</surname><given-names>H.</given-names></name><name><surname>Brooke</surname><given-names>C.B.</given-names></name><pub-id pub-id-type="pmid">30683737</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><source>Front. Immunol.</source><year>2015</year><volume>6</volume><issue>161</issue><name><surname>Carnell</surname><given-names>G.W.</given-names></name><name><surname>Ferrara</surname><given-names>F.</given-names></name><name><surname>Grehan</surname><given-names>K.</given-names></name><name><surname>Thompson</surname><given-names>C.P.</given-names></name><name><surname>Temperton</surname><given-names>N.J.</given-names></name></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><source>MBio.</source><year>2017</year><volume>8</volume><fpage>1</fpage><lpage>12</lpage><name><surname>Rajendran</surname><given-names>M.</given-names></name><name><surname>Nachbagauer</surname><given-names>R.</given-names></name><name><surname>Ermler</surname><given-names>M.E.</given-names></name><name><surname>Bunduc</surname><given-names>P.</given-names></name><name><surname>Amanat</surname><given-names>F.</given-names></name><name><surname>Izikson</surname><given-names>R.</given-names></name><name><surname>Cox</surname><given-names>M.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name><name><surname>Eichelberger</surname><given-names>M.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><source>Rev. Med. Virol.</source><year>2012</year><volume>22</volume><issue>4</issue><fpage>267</fpage><lpage>279</lpage><name><surname>Marcelin</surname><given-names>G.</given-names></name><name><surname>Sandbulte</surname><given-names>M.R.</given-names></name><name><surname>Webby</surname><given-names>R.J.</given-names></name><pub-id pub-id-type="pmid">22438243</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><source>J. Infect. Dis.</source><year>2019</year><volume>219</volume><issue>1</issue><fpage>S75</fpage><lpage>S80</lpage><name><surname>Eichelberger</surname><given-names>M.C.</given-names></name><name><surname>Monto</surname><given-names>A.S.</given-names></name><pub-id pub-id-type="pmid">30715357</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><source>MBio.</source><year>2018</year><volume>9</volume><issue>2</issue><elocation-id>e02332-17</elocation-id><name><surname>Krammer</surname><given-names>F.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.M.</given-names></name><name><surname>Eichelberger</surname><given-names>M.C.</given-names></name><name><surname>Webby</surname><given-names>R.J.</given-names></name><name><surname>Shaw-Saliba</surname><given-names>K.</given-names></name><name><surname>Wan</surname><given-names>H.</given-names></name><name><surname>Compans</surname><given-names>R.W.</given-names></name><name><surname>Skountzou</surname><given-names>I.</given-names></name><name><surname>Monto</surname><given-names>A.S.</given-names></name></element-citation></ref></ref-list></back></article>